Sai Nxt, Sai Life Sciences' Initiative to Turn NextGen CDMO
The contract development and manufacturing organization, Sai Life Sciences announces Sai Nxt, an organization intending to transform the company into a new generation CDMO (Contract Development and Manufacturing Organization). Considering its customer's feedback, the company is investing about $150 million from the period between 2019 and 2023 as a part of Sai Nxt.
In two decades, Sai Life Science has evolved to be one of India's most trusted CDMOs. The company has set Sai Nxt as its transformative lever that would lead the company to the next level of its growth. Through Sai Nxt, Sai Life Sciences is intending to develop and improve its R&D and manufacturing facilities. Also, aims to deepen scientific & technological capabilities, reinforce automation & data systems, Furthermore, the company is looking forward to enhance the safety, quality and customer focus.
The company's main focus is set on three key areas namely people & culture, Processes & automation, infrastructure & scientific capabilities. For people and culture area, Sai Nxt would provide scientific talent pool expansion, role-based integrated online training, nurturing culture of excellence, shop floor transformation. For processes & automation, Sai Nxt brings in process simplification, electronic manufacturing records, strengthening governance systems, the foundation for seamless data capture across operations, leveraging latest technologies (RPA, IOT, AI / ML, AR/ VR) for innovation and intelligence. Lastly, for infrastructure & capabilities, it offers Biology lab in Cambridge (MA, USA), expanded suite of technology platforms, Process R&D lab in Manchester (UK), Integrated Discovery and Development campus, early phase delivery facility, flexible manufacturing with 2.5x capacity, advanced safety & quality systems
"Sai Nxt marks a transformative phase in our journey. Our growth over the years has essentially been driven by our scientific capabilities and customer focus. Raising the bar further, Sai Nxt will help us better serve the growing demand from global innovator pharma and biotech companies for speed and flexibility, with an assurance of compliance and dependability," says Krishna Kanumuri, CEO & Managing Director of Sai Life Sciences.